Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Benzyl-4-Sulfamoyl-Benzamide is a small molecule belonging to the sulfonamide and benzamide chemical classes. It is a potent inhibitor of carbonic anhydrase II (CA II), an enzyme involved in the reversible hydration of carbon dioxide. By inhibiting CA II (EC 4.2.1.1), this compound can modulate physiological processes such as acid-base balance and fluid secretion. Sulfonamides are historically known for their antibacterial properties; however, N-Benzyl-4-Sulfamoyl-Benzamide's primary characterized activity is as a carbonic anhydrase inhibitor rather than as an antibiotic[1][3][5]. The compound has been studied primarily in biochemical and medicinal chemistry research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-benzyl-4-sulfamoyl-benzamide.